370 likes | 457 Views
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA. Goal. Statin Intolerance. Serial IVUS. Effect on CHD Events of Lowering LDL-C. Percent Change in LDL-C During Treatment. Primary Endpoint: PAV. Percent of Patients Showing Regression in PAV.
E N D